Trials / Withdrawn
WithdrawnNCT05950776
COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults
A Multi-center, Randomized Placebo-controlled Phase II Trial to Assess the Safety, Tolerability and Immunogenicity of Two Doses of the Candidate Vaccine MVA-SARS-2-S in Adults Aged 18 to 64 and 65 and Older
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In this multi-center phase II clinical trial, adults in stable health conditions will be vaccinated twice with either a low dose or high dose of the candidate vaccine MVA-SARS-2-S, or placebo. The aim of the study is to assess the safety and immunogenicity of the candidate vaccine.
Detailed description
The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein (S). This will be a combined Phase II, multi-center trial in a total of 580 participants. The dose finding study will be conducted randomized-controlled, in adults in stable health conditions, including health care workers, COVID-19 risk populations, individuals with advanced age and seropositive individuals. Male and female individuals in stable health conditions will be stratified for age (18-64 years and 65 and older).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA-SARS-2-S | Vaccination with MVA-SARS-2-S |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2022-11-02
- Completion
- 2022-11-02
- First posted
- 2023-07-18
- Last updated
- 2023-07-18
Source: ClinicalTrials.gov record NCT05950776. Inclusion in this directory is not an endorsement.